Citius Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a specialty pharmaceutical company focused on developing and commercializing high-barrier-to-entry treatments for critical unmet medical needs in oncology, anti-infectives, and other therapeutic areas. The company offers a pipeline of product candidates including LYMPHIR (denileukin diftitox), a recombinant fusion protein for the treatment of cutaneous T-cell lymphoma; Mino-Lok, a catheter lock solution to treat catheter-related bloodstream infections; and HEALIO (EB-05), a wound care product utilizing a nitric oxide platform for debridement and healing of chronic wounds; as well as partnering on GI-204, an IL-12 immunotherapy for solid tumors. Citius Pharmaceuticals operates primarily in the United States, with its headquarters in Cranford, New Jersey, where it was founded in 2007 as a late-stage asset acquisition company. In recent developments, the company completed a strategic merger with Citius Oncology, Inc. in 2023 to bolster its oncology portfolio, received FDA approval for LYMPHIR in August 2024 following Priority Review, and announced positive topline results from the Phase 3 RESOLVE trial for Mino-Lok in late 2024, paving the way for a New Drug Application filing expected in early 2025; additionally, Citius entered a licensing agreement with Novant Health for commercial rights to certain assets and raised approximately $10 million through a registered direct offering in November 2024 to support pipeline advancement.
Company News
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Now Rated “Hold” by Wall Street Brokerages
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
What's Behind The Drop In Citius Pharmaceuticals?
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Pharmaceuticals (NASDAQ:CTXR) and Klotho Neurosciences (NASDAQ:KLTO) Head-To-Head Comparison